|
WO2007109321A2
(en)
|
2006-03-20 |
2007-09-27 |
The Regents Of The University Of California |
Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
|
|
CA2698343C
(en)
|
2007-09-04 |
2018-06-12 |
The Regents Of The University Of California |
High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
|
|
NZ591087A
(en)
*
|
2008-10-01 |
2012-08-31 |
Micromet Ag |
Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
|
|
US10981998B2
(en)
*
|
2008-10-01 |
2021-04-20 |
Amgen Research (Munich) Gmbh |
Cross-species-specific single domain bispecific single chain antibody
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
SG10201501767VA
(en)
|
2010-03-10 |
2015-05-28 |
Genmab As |
Monoclonal antibodies against c-met
|
|
TWI653333B
(zh)
*
|
2010-04-01 |
2019-03-11 |
安進研究（慕尼黑）有限責任公司 |
跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
|
|
AU2011261161A1
(en)
|
2010-06-01 |
2013-01-10 |
Ludwig Institute For Cancer Research Limited |
Antibodies directed to the unprocessed receptor tyrosine kinase c-Met
|
|
US8603478B2
(en)
|
2010-07-06 |
2013-12-10 |
Aveo Pharmaceuticals, Inc. |
Anti-RON antibodies
|
|
AU2011283694B2
(en)
|
2010-07-29 |
2017-04-13 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
|
UA112062C2
(uk)
|
2010-10-04 |
2016-07-25 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
Cd33-зв'язувальний агент
|
|
KR102447595B1
(ko)
|
2010-11-30 |
2022-09-26 |
추가이 세이야쿠 가부시키가이샤 |
세포상해 유도 치료제
|
|
CA2820782A1
(en)
*
|
2010-12-10 |
2012-06-14 |
Merck Patent Gmbh |
Bispecific aptamers mediating tumour cell lysis
|
|
DE102011118022B4
(de)
*
|
2011-06-30 |
2018-01-18 |
Gemoab Monoclonals Gmbh |
Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
WO2013078223A1
(en)
*
|
2011-11-23 |
2013-05-30 |
Children's Hospital & Research Center Oakland |
Anti-factor h binding protein antibodies and methods of use thereof
|
|
AR089114A1
(es)
|
2011-12-09 |
2014-07-30 |
Amgen Res Munich Gmbh |
PREVENCION DE LOS EFECTOS ADVERSOS CAUSADOS POR LOS ANTICUERPOS BIESPECIFICOS EpCAMxCD3
|
|
US9353153B2
(en)
|
2012-02-09 |
2016-05-31 |
Riken |
Cyclic RNA and protein production method
|
|
US20140004121A1
(en)
|
2012-06-27 |
2014-01-02 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
|
US9931400B2
(en)
|
2012-09-12 |
2018-04-03 |
Samsung Electronics Co., Ltd. |
Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
CA2898100C
(en)
*
|
2013-01-14 |
2023-10-10 |
Xencor, Inc. |
Novel heterodimeric proteins
|
|
CA2897987A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
|
WO2014138306A1
(en)
*
|
2013-03-05 |
2014-09-12 |
Baylor College Of Medicine |
Engager cells for immunotherapy
|
|
EP2970486B1
(en)
|
2013-03-15 |
2018-05-16 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
CN103275225A
(zh)
*
|
2013-05-10 |
2013-09-04 |
洪建� |
高亲合力抗cd31/cd146双特异单克隆抗体及其应用
|
|
WO2015057545A2
(en)
|
2013-10-14 |
2015-04-23 |
Janssen Biotech, Inc. |
Cysteine engineered fibronectin type iii domain binding molecules
|
|
TR201802728T4
(tr)
|
2013-10-25 |
2018-03-21 |
Psioxus Therapeutics Ltd |
Heterolog genlerle donatılmış onkolitik adenovirüsler.
|
|
MX379210B
(es)
|
2014-02-07 |
2025-03-10 |
Univ Mcmaster |
Acoplador trifuncional de antígeno de células t y métodos y usos del mismo.
|
|
EA201691925A1
(ru)
|
2014-03-28 |
2017-06-30 |
Ксенкор, Инк. |
Биспецифические антитела, которые связываются с cd38 и cd3
|
|
WO2015156268A1
(ja)
|
2014-04-07 |
2015-10-15 |
中外製薬株式会社 |
免疫活性化抗原結合分子
|
|
CA2947157A1
(en)
*
|
2014-05-13 |
2015-11-19 |
Chugai Seiyaku Kabushiki Kaisha |
T cell-redirected antigen-binding molecule for cells having immunosuppression function
|
|
WO2015172341A1
(zh)
*
|
2014-05-14 |
2015-11-19 |
上海市肿瘤研究所 |
针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体
|
|
CA2895659A1
(en)
|
2014-07-01 |
2016-01-01 |
Pfizer Inc. |
Bispecific heterodimeric diabodies and uses thereof
|
|
US11661462B2
(en)
|
2014-07-31 |
2023-05-30 |
Amgen Research (Munich) Gmbh |
Optimized cross-species specific bispecific single chain antibody contructs
|
|
KR101615619B1
(ko)
*
|
2014-08-07 |
2016-04-26 |
주식회사 파멥신 |
c-Met 특이적 인간 항체 및 그 제조방법
|
|
WO2016019969A1
(en)
|
2014-08-08 |
2016-02-11 |
Ludwig-Maximilians-Universität München |
Subcutaneously administered bispecific antibodies for use in the treatment of cancer
|
|
ES2850325T3
(es)
|
2014-10-09 |
2021-08-27 |
Engmab Sarl |
Anticuerpos biespecíficos contra CD3epsilon y ROR1
|
|
US20170306044A1
(en)
*
|
2014-10-09 |
2017-10-26 |
Engmab Ag |
Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer
|
|
KR102309881B1
(ko)
|
2014-11-21 |
2021-10-06 |
삼성전자주식회사 |
c-Met 및 EGFR의 이중 저해제 및 IGF-1R 저해제를 포함하는 병용 투여용 약학 조성물
|
|
SI3223605T1
(sl)
*
|
2014-11-24 |
2021-03-31 |
Regeneron Pharmaceuticals, Inc. |
Nehumane živali, ki izražajo humaniziran CD3 kompleks
|
|
SG11201704274QA
(en)
|
2014-11-26 |
2017-06-29 |
Xencor Inc |
Heterodimeric antibodies that bind cd3 and cd38
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
KR20240116967A
(ko)
|
2014-11-26 |
2024-07-30 |
젠코어 인코포레이티드 |
Ｃｄ3 및 종양 항원과 결합하는 이종이량체 항체
|
|
EP3237449A2
(en)
|
2014-12-22 |
2017-11-01 |
Xencor, Inc. |
Trispecific antibodies
|
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
|
PL3298033T5
(pl)
|
2015-05-18 |
2023-10-30 |
TCR2 Therapeutics Inc. |
Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
HK1254967A1
(zh)
*
|
2015-10-02 |
2019-08-02 |
豪夫迈‧罗氏有限公司 |
结合间皮素和cd3的双特异性t细胞活化性抗原结合分子
|
|
US10858423B2
(en)
|
2015-10-26 |
2020-12-08 |
Pierre Fabre Medicament |
Composition for the treatment of IGF-1R expressing cancer
|
|
JP6925278B2
(ja)
|
2015-11-18 |
2021-08-25 |
中外製薬株式会社 |
液性免疫応答の増強方法
|
|
WO2017086367A1
(ja)
|
2015-11-18 |
2017-05-26 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
|
|
CN106810610A
(zh)
*
|
2015-11-30 |
2017-06-09 |
中国科学院深圳先进技术研究院 |
抗EpCAM和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用
|
|
CN106810611A
(zh)
*
|
2015-11-30 |
2017-06-09 |
中国科学院深圳先进技术研究院 |
抗cMet和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用
|
|
TW201720458A
(zh)
*
|
2015-12-04 |
2017-06-16 |
宏觀基因股份有限公司 |
能夠結合cd19 和cd3 的雙特異性單價雙抗體以及其用途
|
|
AU2016365742A1
(en)
|
2015-12-07 |
2018-06-21 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and PSMA
|
|
JP7064437B2
(ja)
|
2015-12-17 |
2022-05-10 |
サイオクサス セラピューティクス リミテッド |
抗ｔｃｒ複合体抗体又は断片をコードするｂ群アデノウイルス
|
|
EP3851457A1
(en)
|
2016-01-21 |
2021-07-21 |
Novartis AG |
Multispecific molecules targeting cll-1
|
|
HUE068801T2
(hu)
|
2016-06-14 |
2025-01-28 |
Xencor Inc |
Bispecifikus kontrollpont-gátló antitestek
|
|
KR20230129583A
(ko)
|
2016-06-21 |
2023-09-08 |
테네오바이오, 인코포레이티드 |
Cd3 결합 항체
|
|
WO2018005706A1
(en)
|
2016-06-28 |
2018-01-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
|
CN107573416A
(zh)
*
|
2016-06-30 |
2018-01-12 |
中国科学院深圳先进技术研究院 |
抗igf1r和cd3特异性双靶向抗体、含该双靶向抗体表达盒的微环dna及应用
|
|
MX2018015414A
(es)
*
|
2016-06-30 |
2019-08-01 |
Hoffmann La Roche |
Terapia de célula t adoptiva mejorada.
|
|
TWI790206B
(zh)
*
|
2016-07-18 |
2023-01-21 |
法商賽諾菲公司 |
特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
|
|
WO2018026953A1
(en)
|
2016-08-02 |
2018-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
IL264902B2
(en)
*
|
2016-08-29 |
2023-11-01 |
Akamis Bio Ltd |
Adenovirus with bispecific T cell activator
|
|
GB201713765D0
(en)
|
2017-08-28 |
2017-10-11 |
Psioxus Therapeutics Ltd |
Modified adenovirus
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
HRP20240767T1
(hr)
|
2016-09-14 |
2024-09-13 |
Teneoone, Inc. |
Cd3 vezujuća antitijela
|
|
GB2564823B8
(en)
|
2016-10-07 |
2022-06-29 |
Tcr2 Therapeutics Inc |
Compositions and methods for TCR reprogramming using fusion proteins
|
|
KR102562519B1
(ko)
|
2016-10-14 |
2023-08-02 |
젠코어 인코포레이티드 |
IL-15/IL-15Rα FC-융합 단백질 및 PD-1 항체 단편을 포함하는 이중특이성 이종이량체 융합 단백질
|
|
CA3044593A1
(en)
|
2016-11-22 |
2018-05-31 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
KR102633423B1
(ko)
|
2016-12-21 |
2024-02-06 |
테네오바이오, 인코포레이티드 |
항-bcma 중쇄-단독 항체
|
|
WO2018224441A1
(en)
*
|
2017-06-05 |
2018-12-13 |
Numab Innovation Ag |
Novel anti-cd3 antibodies
|
|
EP3634998B8
(en)
|
2017-06-05 |
2025-04-09 |
Numab Therapeutics AG |
Anti-cd3 epsilon antibodies
|
|
CA3067584A1
(en)
|
2017-06-20 |
2018-12-27 |
Teneobio, Inc. |
Anti-bcma heavy chain-only antibodies
|
|
CA3065328C
(en)
|
2017-06-21 |
2023-08-15 |
Gilead Sciences, Inc. |
Multispecific antibodies that target hiv gp120 and cd3
|
|
EP3645122A1
(en)
|
2017-06-30 |
2020-05-06 |
Xencor, Inc. |
Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
|
|
ES2973864T3
(es)
*
|
2017-08-10 |
2024-06-24 |
Grifols Diagnostic Solutions Inc |
Composiciones, métodos y/o kits que comprenden un dominio extracelular de CD38 recombinante humano
|
|
EP3694997A4
(en)
|
2017-10-12 |
2021-06-30 |
Mcmaster University |
T cell-antigen coupler with y182t mutation and methods and uses thereof
|
|
DE102017125150B4
(de)
*
|
2017-10-26 |
2019-10-10 |
Epiontis Gmbh |
Endosialin (CD248) als epigenetischer Marker zur Identifizierung von Immunzellen, insbesondere naïver CD8+ T-Zellen
|
|
CN112272563A
(zh)
|
2017-11-08 |
2021-01-26 |
Xencor股份有限公司 |
使用新颖抗pd-1序列的双特异性和单特异性抗体
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
SG11202005732XA
(en)
|
2017-12-19 |
2020-07-29 |
Xencor Inc |
Engineered il-2 fc fusion proteins
|
|
WO2019133847A1
(en)
|
2017-12-29 |
2019-07-04 |
Oncorus, Inc. |
Oncolytic viral delivery of therapeutic polypeptides
|
|
US12162920B2
(en)
*
|
2018-01-26 |
2024-12-10 |
Chongqing Precision Biotech Company Limited |
Hinge area and use of same in constructing car skeleton
|
|
CA3096052A1
(en)
*
|
2018-04-04 |
2019-10-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
KR20210010862A
(ko)
|
2018-04-18 |
2021-01-28 |
젠코어 인코포레이티드 |
IL-15/IL-15Rα Fc-융합 단백질 및 PD-1 항원 결합 도메인을 함유하는 PD-1 표적화 이종이량체 융합 단백질 및 이의 용도
|
|
JP2021520829A
(ja)
|
2018-04-18 |
2021-08-26 |
ゼンコア インコーポレイテッド |
ＩＬ−１５／ＩＬ−１５ＲＡ Ｆｃ融合タンパク質およびＴＩＭ−３抗原結合ドメインを含む、ＴＩＭ−３標的化ヘテロ二量体融合タンパク質
|
|
MX2020012495A
(es)
|
2018-06-01 |
2021-02-15 |
Novartis Ag |
Moleculas de union contra bcma y usos de las mismas.
|
|
US10640562B2
(en)
|
2018-07-17 |
2020-05-05 |
Mcmaster University |
T cell-antigen coupler with various construct optimizations
|
|
US11110123B2
(en)
|
2018-07-17 |
2021-09-07 |
Triumvira Immunologics Usa, Inc. |
T cell-antigen coupler with various construct optimizations
|
|
JP7612571B2
(ja)
|
2018-10-03 |
2025-01-14 |
ゼンコア インコーポレイテッド |
Ｉｌ－１２ヘテロ二量体ｆｃ－融合タンパク質
|
|
IT201800009282A1
(it)
*
|
2018-10-09 |
2020-04-09 |
Metis Prec Medicine Sb Srl |
Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
|
|
MX2021006389A
(es)
*
|
2018-12-07 |
2021-07-15 |
Jiangsu Hengrui Medicine Co |
Anticuerpo cd3 y uso farmaceutico del mismo.
|
|
MX2021010390A
(es)
|
2019-03-01 |
2021-11-17 |
Xencor Inc |
Anticuerpos heterodimericos que se unen a enpp3 y cd3.
|
|
JOP20210253A1
(ar)
|
2019-04-05 |
2023-01-30 |
Teneobio Inc |
أجسام مضادة ذات سلسلة ثقيلة ترتبط بـ psma
|
|
CU20210096A7
(es)
|
2019-05-21 |
2022-06-06 |
Novartis Ag |
Moléculas de unión a cd19
|
|
AR119746A1
(es)
|
2019-06-14 |
2022-01-05 |
Teneobio Inc |
Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
|
|
WO2021006199A1
(ja)
|
2019-07-05 |
2021-01-14 |
小野薬品工業株式会社 |
Ｐｄ－１／ｃｄ３二重特異性タンパク質による血液がん治療
|
|
US11766453B2
(en)
|
2019-09-11 |
2023-09-26 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods comprising prostate stem cell antigen (PSCA) chimeric antigen receptors (CARs)
|
|
KR20220131221A
(ko)
|
2019-11-13 |
2022-09-27 |
아뮤닉스 파마슈티컬스, 인크. |
바코드화된 xten 폴리펩티드 및 이의 조성물, 및 이의 제조 방법 및 사용 방법
|
|
EP4045541A4
(en)
*
|
2019-12-20 |
2023-08-16 |
Shandong Boan Biotechnology Co., Ltd. |
Optimized anti-cd3 arm in the generation of t-cell bispecific antibodies for immunotherapy
|
|
WO2021155380A1
(en)
*
|
2020-01-31 |
2021-08-05 |
Gensun Biopharma Inc. |
Bispecific t cell engagers
|
|
US20230075244A1
(en)
*
|
2020-02-20 |
2023-03-09 |
The Feinstein Institutes For Medical Research |
Agonist antibodies against endoglin and uses thereof
|
|
AU2021263448A1
(en)
|
2020-04-29 |
2022-11-24 |
Teneobio, Inc. |
Multispecific heavy chain antibodies with modified heavy chain constant regions
|
|
JP2023529557A
(ja)
|
2020-05-04 |
2023-07-11 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
抗ｅｎｐｐ１抗体の阻害
|
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
|
EP4153634A4
(en)
*
|
2020-05-19 |
2024-05-29 |
City of Hope |
GENETICALLY MODIFIED ANTI-PROSTATIC STEM CELL ANTIGEN FUSION PROTEINS AND USES THEREOF
|
|
IL298815A
(en)
|
2020-06-25 |
2023-02-01 |
Amunix Pharmaceuticals Inc |
Bispecific compositions targeting HER-2 and methods for their preparation and use
|
|
CN115698072B
(zh)
|
2020-07-01 |
2023-07-04 |
山东博安生物技术股份有限公司 |
抗gpc3抗体，抗gpc3嵌合抗原受体和gpc3/cd3双特异性抗体
|
|
AU2021329378A1
(en)
|
2020-08-19 |
2023-03-23 |
Xencor, Inc. |
Anti-CD28 compositions
|
|
CN112063608B
(zh)
*
|
2020-08-27 |
2022-06-17 |
浙江工业大学 |
一种脂肪酸光脱羧酶突变体及其在l-草铵膦合成中的应用
|
|
IL305736A
(en)
|
2021-03-09 |
2023-11-01 |
Xencor Inc |
Heterodimeric antibodies that bind cd3 and cldn6
|
|
KR20230154311A
(ko)
|
2021-03-10 |
2023-11-07 |
젠코어 인코포레이티드 |
Cd3 및 gpc3에 결합하는 이종이량체 항체
|
|
WO2022256449A1
(en)
|
2021-06-01 |
2022-12-08 |
Triumvira Immunologics Usa, Inc. |
Claudin 18.2 t cell-antigen couplers and uses thereof
|
|
US11453723B1
(en)
|
2021-06-25 |
2022-09-27 |
Mcmaster University |
BCMA T cell-antigen couplers and uses thereof
|
|
CN115536740A
(zh)
*
|
2021-06-30 |
2022-12-30 |
苏州方德门达新药开发有限公司 |
介导细胞内有效滞留cd3的空间构象表位及其应用
|
|
EP4435006A1
(en)
*
|
2021-11-19 |
2024-09-25 |
Wuhan Yzy Biopharma Co., Ltd. |
Bispecific antibody and use thereof
|
|
US20240165213A1
(en)
*
|
2022-11-21 |
2024-05-23 |
Avstera Therapeutics Corp. |
mRNA COMPOSITION FOR PREVENTING AND TREATING CANCER
|
|
WO2024168279A2
(en)
|
2023-02-10 |
2024-08-15 |
Amunix Pharmaceuticals, Inc. |
Compositions targeting prostate-specific membrane antigen (psma) and methods for making and using the same
|
|
WO2024220397A1
(en)
|
2023-04-17 |
2024-10-24 |
Amunix Pharmaceuticals, Inc. |
Compositions targeting epidermal growth factor receptor and methods for making and using the same
|
|
CN116790744B
(zh)
*
|
2023-06-30 |
2024-04-26 |
浙江大学 |
一种缺血性心脏病晚期纤维化干预靶点及其应用
|
|
TW202534086A
(zh)
*
|
2024-02-28 |
2025-09-01 |
香港商Ｆｂｄ生物製劑有限公司 |
抗ｐｓｃａ抗體及其用途
|